Diligence memo · auto-generated · as of July 2, 2026

Dermelle, LLC

Dermelle, LLC looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Dermelle, LLC operates in Biotechnology, based in COLUMBIA.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Dermelle, LLC has raised $9.4M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.5M on —.

Most recent recorded round closed around 2013-05-05.

Valuation (modeled)modeled

Provath models Dermelle, LLC at approximately $90M (range $1.5M–$703M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.56× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 173 months.

Last raise 13.2 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 55% of Biotechnology peers (4293 compared).

Modeled value ranks above 57% of those peers.

Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc..

Peoplefiled

13 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.